Avalon Pharma Saudi Arabia signs an agreement to register and market dupilumab in the Middle East

The Middle East Pharmaceutical Industries Company (Avalon Pharma) announced the signing of a strategic marketing agreement with Bio-Thera Solutions, under which it obtains exclusive rights to register and market the drug “Dupilumab” (a generic product of “Dupixent”) in the Kingdom of Saudi Arabia and the Middle East and North Africa region.

According to the company’s statement on the Saudi Stock Exchange’s “Tadawul” website today, Tuesday, the value of this contract represents less than 5% of the company’s total revenues.

Based on the annual financial statements for the fiscal year ending on December 31, 2025.

The company noted that the agreement grants it exclusive licensing rights to register and market the drug “Dupilumab” (a generic product of “Dupixent”) in the Kingdom of Saudi Arabia and in the Middle East and North Africa region, with additional rights to localize the manufacturing of the product in the future.

•The Japanese yen deepens its losses to the lowest level in 3 weeks. •The dollar rebounds and oil rises due to...

Fears of renewed Iranian war • Yields on Japanese bonds jump to the highest level in 30 years • Markets await more evidence about the path of Japanese interest rates

•The US dollar rebounds against a basket of currencies •Oil prices reach the highest level in 3 weeks •The expiration of the temporary peace agreement between the United States and Iran •Markets await the minutes of the Federal Reserve meeting •Trust fund holdings jump to the highest level in 3

months

•The US dollar is trying to recover from low levels. •International oil prices rise for the third day in a row. •The end of the temporary peace agreement between the United States and Iran. •Markets are waiting for new updates on the path of British interest rates.